Gene · 4486
MST1R: macrophage stimulating 1 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MST1R: macrophage stimulating 1 receptor. Genes, record 4486. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4486
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q04912 | Macrophage-stimulating protein receptor | 1,400 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 3727 | Q04912 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 482 | Q04912 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3306 | Q04912 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2723 | Q04912 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2723 | Q04912 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 482 | Q04912 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3306 | Q04912 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 3727 | Q04912 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 48021 | Q04912 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 2656 | Q04912 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CRIZOTINIB | CHEMBL601719 | Macrophage-stimulating protein receptor inhibitor | INHIBITOR | ChEMBL |
| GLESATINIB | CHEMBL3989914 | Macrophage-stimulating protein receptor inhibitor | INHIBITOR | ChEMBL |
| MK-8033 | CHEMBL2323775 | Macrophage-stimulating protein receptor inhibitor | INHIBITOR | ChEMBL |
| NARNATUMAB | CHEMBL1743046 | Macrophage-stimulating protein receptor inhibitor | INHIBITOR | ChEMBL |
Trials96
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07560410 | CRIZOTINIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07207278 | CRIZOTINIB | ClinicalTrials.gov | ||
| NCT06563999 | CRIZOTINIB | PHASE2 | ClinicalTrials.gov | |
| NCT06360575 | CRIZOTINIB | PHASE2 | 2026-03-20 | ClinicalTrials.gov |
| NCT06357975 | CRIZOTINIB | PHASE2 | 2026-03-19 | ClinicalTrials.gov |
| NCT06140836 | CRIZOTINIB | PHASE3 | ClinicalTrials.gov | |
| NCT05987332 | CRIZOTINIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT05834348 | CRIZOTINIB | 2025-03-30 | ClinicalTrials.gov | |
| NCT05792644 | CRIZOTINIB | ClinicalTrials.gov | ||
| NCT05725200 | CRIZOTINIB | PHASE2 | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsNIH grants1,173
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MST1R papers | Newest fiscal year |
|---|---|---|---|
| I01BX000803 | Ron Receptor Tyrosine Kinase Signaling in Breast Cancer | 25 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 8 | 2025 |
| P30DK078392 | Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease | 6 | 2025 |
| T32CA121938 | UCSD Cancer Center Training Program in Drug Development | 6 | 2025 |
| P01CA013106 | Targeting Transcription and Splicing in Cancer | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 5 | 2025 |
| P30CA042014 | Cancer Center Support Grant | 5 | 2025 |
| P30CA047904 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 1,173Source NIH's project files
See all 1,173 nih grantsPapers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of quinoline-based derivatives as c-Met inhibitors for the treatment of non-small cell lung cancer. | Eur J Med Chem | 2026 | 42748863 | PubTator, text mining | PubMed |
| Pharmaceutical Potential of Antibody-Drug Conjugate Doublets for Targeted Treatment of Cancers Heterogeneously Expressing RON Receptor Tyrosine Kinase. | Curr Cancer Drug Targets | 2026 | 42693721 | PubTator, text mining | PubMed |
| RON receptor tyrosine kinase regulates abiraterone resistance in prostate cancer via the methylation-dependent and independent dual functions of DNMT1. | Oncogene | 2026 | 42498731 | PubTator, text mining | PubMed |
| Genome-wide pleiotropic analysis identifies shared genetic architecture within the cognition-immune nexus. | Transl Psychiatry | 2026 | 42386713 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges. | Cancer Chemother Pharmacol | 2026 | 42207299 | PubTator, text mining | PubMed |
| Relation of Osteopontin Expression to Tumor-Associated Macrophages-Derived Transforming Growth Factor Beta 1 Expression in Non-small Cell Lung Carcinoma. | J Microsc Ultrastruct | 2026 | 42040212 | PubTator, text mining | PubMed |
| Investigation of molecular immune regulation mechanisms and therapeutic target prediction in pancreatic cancer based on bioinformatics and genetics. | Clinics (Sao Paulo) | 2026 | 42001564 | PubTator, text mining | PubMed |
| Expression and Clinical Significance of Pim-1 and RON in Lung Cancer Patients with Benign and Malignant Pleural Effusion. | Clin Lab | 2026 | 41979639 | PubTator, text mining | PubMed |
| Osteosarcoma cells promote intracellular iron detoxification to mitigate GPX4-mediated ferroptosis. | Cancer Gene Ther | 2026 | 41872463 | PubTator, text mining | PubMed |
| Genomic landscape of pleural mesothelioma in Japanese patients: A comprehensive analysis using nationwide database. | Transl Oncol | 2026 | 41855858 | PubTator, text mining | PubMed |
1 to 10 of 1,924
See all 1,924 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4486
GET https://conductscience.org/api/genes/v1/4486/patents?page=2